{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-067444","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.724862+00:00","generated_at":"2026-05-18T06:59:35.144227+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Liminatus Pharma appoints Philip Lemons and Richard Baek to Board of Directors","bullets":["Board expanded from 5 to 6 members with appointment of Lemons and Baek effective July 10, 2025.","Philip Lemons, 54, brings clinical R&D expertise; serves as Chief Business Officer at ICE Global Consulting.","Richard Baek, 33, brings financial oversight and regulatory compliance; VP Finance at Studio City PXL.","No arrangements or transactions with the company requiring disclosure under Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-067444","json":"https://secwatch.observer/filing/0001104659-25-067444.json","markdown":"https://secwatch.observer/filing/0001104659-25-067444.md","text":"https://secwatch.observer/filing/0001104659-25-067444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925067444/0001104659-25-067444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925067444/tm2520692d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:59:35.144227+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}